February 13, 2008 at 7:26 pm
· Filed under updates
Related to the last update, Genentech announced that they are not going ahead with rituxan for RRMS (they are continuing with the PPMS trial). The reason is that ocrelizumab goes after the same target and they are concentrating on that drug for RRMS. I removed Rituxan from the phase 2 list.
